Undiagnosed progressive supranuclear palsy in a patient with neuroleptic malignant syndrome due to use of neuroleptics: The utility of autopsy in deaths due to known drug reactions

American Journal of Forensic Medicine and Pathology

Volumn 28, Issue 1, 2007, Pages 59-62

  Kemp, Walter L ^a,b   Fitzgerald, John ^a   White III, Charles L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Forensic Science Division   (United States)

Author keywords

Autopsy; Neuroleptic malignant syndrome; Progressive supranuclear palsy

Indexed keywords

ANTIBIOTIC AGENT; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; QUETIAPINE; SERTRALINE; TAU PROTEIN;

ADULT; ANAMNESIS; ARTICLE; AUTOPSY; CASE REPORT; CAUSE OF DEATH; CHOREOATHETOSIS; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; ELECTROENCEPHALOGRAM; FEMALE; FINGER AMPUTATION; HUMAN; HUMAN TISSUE; NEUROLEPTIC MALIGNANT SYNDROME; OSTEOMYELITIS; PATHOLOGIST; PROGRESSIVE SUPRANUCLEAR PALSY; RHABDOMYOLYSIS; SCHIZOAFFECTIVE PSYCHOSIS; STAPHYLOCOCCUS AUREUS; BRAIN; FORENSIC PATHOLOGY; PATHOLOGY; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; FEMALE; FORENSIC PATHOLOGY; HALOPERIDOL; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOTIC DISORDERS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 34147174847     PISSN: 01957910     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.paf.0000221054.83813.8e     Document Type: Article

References (12)

1. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci. 2001;24:347-352.
2. Ellison D, Love S, Chimelli L, et al. Neuropathology. London, UK: Mosby; 1998:28.6-28.8.
3. Rajput A, Rajput AH. Progressive supranuclear palsy: clinical features, pathophysiology and management. Drugs Aging. 2001;18:913-925.
4. Mochizuki A, Ueda Y, Komatsuzaki Y, et al. Progressive supranuclear palsy presenting with primary progressive aphasia: clinicopathological report of an autopsy case. Acta Neuropathol. 2003;105:610-614.
5. Bigio EH, Brown DF, White CL. Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol. 1999;58:359-364.
6. Litvan I, Mega MS, Cummings JL, et al. Neuropsychiatric aspect of progressive supranuclear palsy. Neurology. 1996;47:1184-1189.
7. Nicholson D, Chiu W. Neuroleptic malignant syndrome. Geriatrics. 2004;59:36-40.
8. Mizuno Y, Takubo H, Mizuta E, et al. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord. 2003;9:S3-S9.
9. Harada T, Mitsuoka K, Kumagai R, et al. Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders. Parkinsonism Relat Disord. 2003;9:S15-S23.
10. Jahan MS, Farooque AI, Wahid Z. Neuroleptic malignant syndrome. J Natl Med Assoc. 1992;84:966-970.
11. Wren P, Frizzel LA, Keltner NL, et al. Three potentially fatal adverse effects of psychotropic medications. Perspect Psychiatric Care. 2003;39:75-81.
12. Yoshikawa H, Oda Y, Skajiri K, et al. Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive supranuclear palsy. Acta Neuropathol. 1997;93:306-309.